Technical Data Sheet
Tesamorelin
Also Known As: Egrifta, Egrifta SV, TH9507, Tesamorelin acetate, Trans-3-hexenoic acid GHRH, Modified GHRH analog Egrifta, HIV lipodystrophy treatment peptide, GHRH analog tesamorelin, Liver fat peptide treatment, Cognitive GHRH analog, GHRH, tesa, tesamorelin acetate
Scan To View Profile
| Evidence Tier | Approved Drug |
|---|---|
| Category | Muscle Growth & Performance |
| Class | Synthetic GHRH analog with trans-3-hexenoic acid modification at N-terminus; FDA-approved for HIV lipodystrophy |
| Molecular Target | GHRH receptor (GHRHR) on pituitary somatotrophs; GH/IGF-1 axis stimulation; preferential visceral fat metabolism |
| Sequence | hGHRH(1-44) with trans-3-hexenoyl |
| Molecular Weight | ~5136 Da |
| CAS | 218949-48-5 |
| Parent | Growth hormone releasing hormone |
| Mechanism | It is a highly stable GHRH analogue that binds to the pituitary to release growth hormone. Uniquely, its specific pulsatile effect heavily targets the breakdown of visceral adipose tissue (deep belly fat). |
| Studied For | HIV-associated lipodystrophy (FDA approved), Hepatic fat / NAFLD research, Cognition research in aging/HIV, GH deficiency, Body composition improvement, Visceral adipose reduction, Liver fat reduction, GH axis stimulation, IGF-1 elevation, Cardiovascular lipid profile improvement, Cognitive decline in aging HIV+ population, Anti-aging via GH axis, Non-alcoholic fatty liver disease, Lean mass support, visceral fat reduction, belly fat, HIV lipodystrophy, muscle growth, body composition, lipid profile improvement, cognitive function |
| Administration Route | Injection Only |
| Form | lyophilized |
| Diluent | sterile water |
| Storage Temperature | per formulation (room temp or refrigerated); follow label |
| Light Sensitive | Yes |
| Freeze / Thaw | avoid |
| Reconstituted Shelf Life | 1 Days |
| Handling Notes | Daily subcutaneous; improper reconstitution causes aggregation. |
| Regulatory | FDA-approved (Egrifta) for HIV lipodystrophy; WADA S2. |
| Sources |